Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Collaborative Health Research Projects

University of British Columbia

$139,462.00

Radiometals produced by liquid targets for molecular imaging of cancer

EF 2012-13

Résumé
New breast cancer drugs are increasingly targeted to specific proteins involved in cancer progression, such as the epidermal growth factor receptor (HER2). These new drugs typically benefit only a small proportion of patients, at very high cost to the health care system (over $40,000 per patient per year for Herceptin, which targets HER2). Physicians need information about whether a drug target is present in patients' tumours before selecting these expensive treatments. The presence of a predictive protein, also called a biomarker, can be determined by taking a tumour biopsy using special laboratory techniques. However, it is often impossible to biopsy tumours that have spread, and biomarker content may vary from one tumour site to another. Molecular imaging technologies such as positron emission tomography combined with computed tomography (PET/CT) can be a powerful, non invasive tool to detect biomarkers, using extremely low concentrations of radioactive probes. The purpose of this project is to develop novel radioisotope production technologies used for PET/CT imaging. With these radioisotopes, the project will develop new imaging agents that will allow physicians to find out if patients express a variant of HER2 that is associated with resistance to the current drug used to treat HER2 positive breast cancers. The radioisotopes of interest are called zirconium-89, gallium-68, yttrium-86 and scandium-44. Many of these radioisotopes are currently unavailable in Canada. The traditional production methods to make them involve the use of solid targets, which are irradiated by a cyclotron, but this approach requires specific equipment and expertise unavailable in most facilities. Our multidisciplinary team of experts, along with our collaborators and industrial partner, will conduct theoretical simulation of radioisotope production yields, design new salt-solution targets to make the radioisotopes, optimize the production conditions of these radioisotopes, develop methods to separate and purify them, and attach the isotopes to
Programme
Collaborative Health Research Projects
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
413841-2012
Name nom
Bénard, François
Department département
Radiology
Organization id
2
Institution établissement
University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2012
Competition year année de concours
2012
Award amount
139462
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
518
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Medical equipment and apparatus
Area of application fr
Appareils et instruments médicaux
Research subject code
9000
Research subject group en
Medical sciences
Research subject group fr
Sciences médicales
Research subject en
Medical sciences
Research subject fr
Sciences médicales
Partie
1
Nb partie
3
Application title
Radiometals produced by liquid targets for molecular imaging of cancer
Keyword
NSERC
Application summary
New breast cancer drugs are increasingly targeted to specific proteins involved in cancer progression, such as the epidermal growth factor receptor (HER2). These new drugs typically benefit only a small proportion of patients, at very high cost to the health care system (over $40,000 per patient per year for Herceptin, which targets HER2). Physicians need information about whether a drug target is present in patients' tumours before selecting these expensive treatments. The presence of a predictive protein, also called a biomarker, can be determined by taking a tumour biopsy using special laboratory techniques. However, it is often impossible to biopsy tumours that have spread, and biomarker content may vary from one tumour site to another. Molecular imaging technologies such as positron emission tomography combined with computed tomography (PET/CT) can be a powerful, non invasive tool to detect biomarkers, using extremely low concentrations of radioactive probes. The purpose of this project is to develop novel radioisotope production technologies used for PET/CT imaging. With these radioisotopes, the project will develop new imaging agents that will allow physicians to find out if patients express a variant of HER2 that is associated with resistance to the current drug used to treat HER2 positive breast cancers. The radioisotopes of interest are called zirconium-89, gallium-68, yttrium-86 and scandium-44. Many of these radioisotopes are currently unavailable in Canada. The traditional production methods to make them involve the use of solid targets, which are irradiated by a cyclotron, but this approach requires specific equipment and expertise unavailable in most facilities. Our multidisciplinary team of experts, along with our collaborators and industrial partner, will conduct theoretical simulation of radioisotope production yields, design new salt-solution targets to make the radioisotopes, optimize the production conditions of these radioisotopes, develop methods to separate and purify them, and attach the isotopes to